Farxiga could become the first SGLT2 inhibitor approved to treat patients with chronic kidney disease, with and without type-2 diabetes

Attachments

  • Original document
  • Permalink

Disclaimer

AstraZeneca plc published this content on 06 January 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 January 2021 07:03:02 UTC